Entering text into the input field will update the search result below

MediWound completes enrollment in late-stage study of NexoBrid

Jun. 11, 2018 8:06 AM ETMediWound Ltd. (MDWD) StockBy: Douglas W. House, SA News Editor
  • MediWound (NASDAQ:MDWD) completes the enrollment of 175 subjects in its Phase 3 DETECT study assessing NexoBrid in severe burn and wound management. Topline results should be available by year-end.
  • The primary endpoint is the proportion of patients experiencing complete eschar removal compared to gel vehicle (placebo) or standard of care. Long-terms effects will be assessed at months 12 and 24.
  • Results from a recent Europe-based Phase 3 showed a 96.3% rate of eschar removal with NexoBrid.

Recommended For You

More Trending News

About MDWD Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
MDWD--
MediWound Ltd.